Yixintang Pharmaceutical Group Co Ltd
SZSE:002727
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Yixintang Pharmaceutical Group Co Ltd
Net Income (Common)
Yixintang Pharmaceutical Group Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Yixintang Pharmaceutical Group Co Ltd
SZSE:002727
|
Net Income (Common)
¥90.2m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-12%
|
|
|
D
|
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
|
Net Income (Common)
¥1.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
LBX Pharmacy Chain JSC
SSE:603883
|
Net Income (Common)
¥395.1m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
5%
|
|
|
Yifeng Pharmacy Chain Co Ltd
SSE:603939
|
Net Income (Common)
¥1.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
16%
|
CAGR 10-Years
25%
|
|
|
ShuYu Civilian Pharmacy Corp Ltd
SZSE:301017
|
Net Income (Common)
-¥188.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Anhui Huaren Health Pharmaceutical Co Ltd
SZSE:301408
|
Net Income (Common)
¥137.7m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Yixintang Pharmaceutical Group Co Ltd
Glance View
In the ever-evolving landscape of China’s healthcare industry, Yixintang Pharmaceutical Group Co Ltd stands as a testament to strategic growth and adaptability. Originating from the bustling city of Kunming, Yixintang has crafted a substantial presence since its inception by immersing itself deeply within local communities. The company operates an extensive network of retail pharmacies, strategically located to serve China’s growing urban and suburban populations. This widespread presence allows Yixintang to cater directly to the everyday health needs of its customers, stocking a diverse array of pharmaceutical products, including prescription drugs, over-the-counter medications, and health supplements. By investing in a robust supply chain and leveraging technology to optimize inventory management, Yixintang ensures its shelves are always well-stocked to meet consumer demands. Beyond its thriving retail operations, Yixintang has diversified its revenue streams by delving into wholesale and distribution, thereby expanding its footprint across the healthcare ecosystem. The company has also invested in its own branded product lines, expanding its horizons beyond mere distribution to manufacturing, which helps enhance its profit margins. This strategic vertical integration, alongside a focus on mergers and acquisitions, has enabled Yixintang to scale efficiently while maintaining a competitive edge. By fostering strong supplier relationships and a customer-centric approach, Yixintang continues to solidify its position as a crucial player in China’s pharmaceutical sector, capturing the hearts and trust of a vast consumer base seeking reliable healthcare solutions.
See Also
What is Yixintang Pharmaceutical Group Co Ltd's Net Income (Common)?
Net Income (Common)
90.2m
CNY
Based on the financial report for Sep 30, 2025, Yixintang Pharmaceutical Group Co Ltd's Net Income (Common) amounts to 90.2m CNY.
What is Yixintang Pharmaceutical Group Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-12%
Over the last year, the Net Income (Common) growth was -42%. The average annual Net Income (Common) growth rates for Yixintang Pharmaceutical Group Co Ltd have been -52% over the past three years , -34% over the past five years , and -12% over the past ten years .